For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Rani Therapeutics Holdings Inc (NASDAQ:RANI) experienced an 18% jump in its stock price following news that the ...

By Nancy Lapid (Reuters) -GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San ...

(HealthDay News) — From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July ...

Sweetener consumption and genetic predisposition are independently associated with the risk for central precocious puberty (CPP), according to a study presented at ENDO 2025, the annual meeting of the ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

T is a Novel, Non-Aromatizing Androgen, Offering the Benefits of Testosterone Without Converting to Estradiol Addressing a ...

Obesity-related cancer deaths in the U.S. have tripled in just two decades, with women, older adults, and minority groups ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...